Researchers identified a critical protein modification called S100a9 lactylation that drives harmful inflammation during heart attack recovery. This modification occurs in neutrophils (immune cells) and triggers their migration to the heart, worsening tissue damage. The study used genetically modified mice lacking this modification, which showed dramatically improved heart function and reduced inflammation after heart attacks. The findings reveal a new therapeutic target and potential biomarker for heart attack patients.
